Analysis of epidermal growth factor-induced NF-κB signaling

Methods in Molecular Biology

Volumn 1280, Issue , 2015, Pages 75-102

  Jiang, Changying ^a   Lin, Xin ^a  

^a NONE

Author keywords

BCL10; CARMA3; EGF; EGFR; EMSA; IKK; I B ; NF B; P65

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR; LUCIFERASE; PROTEIN BINDING; SMALL INTERFERING RNA;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; CULTURE TECHNIQUE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PROCEDURES; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; NF-KAPPA B; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84924373173     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2422-6_6     Document Type: Article

References (33)

1. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18(18):2195–2224
2. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF- [kappa]B activity. Annu Rev Immunol 18: 621–663
3. Baud V, Jacque E (2008) The alternative NF-kB activation pathway and cancer: friend or foe? Med Sci (Paris) 24(12):1083–1088
4. Dolcet X et al (2005) NF-kB in development and progression of human cancer. Virchows Arch 446(5):475–482
5. Feinman R, Siegel DS, Berenson J (2004) Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol 2(3):162–166
6. Giuliani C et al (2001) Nf-kB transcription factor: role in the pathogenesis of inflammatory, autoimmune, and neoplastic diseases and therapy implications. Clin Ter 152(4):249–253
7. Ivanenkov YA, Balakin KV, Lavrovsky Y (2011) Small molecule inhibitors of NF-kB and JAK/ STAT signal transduction pathways as promising anti-inflammatory therapeutics. Mini Rev Med Chem 11(1):55–78
8. Salminen A et al (2008) Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev 7(2):83–105
9. Hideshima T et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277(19):16639–16647
10. Biswas DK et al (2003) Apoptosis caused by chemotherapeutic inhibition of nuclear factor- kappaB activation. Cancer Res 63(2): 290–295
11. Biswas DK et al (2005) Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE 2005(288):pe27
12. Wang Z et al (2006) Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res 66(15):7653–7660
13. Ando K et al (2005) Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefi-tinib. Clin Cancer Res 11(24 Pt 1):8872–8879
14. Le Page C et al (2005) EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 65(2): 130–140
15. Shimizu M et al (2005) Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor- 2 signaling pathways in human colon cancer cells. Clin Cancer Res 11(7):2735–2746
16. Marciniak DJ et al (2004) Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells. Mol Cancer Ther 3(12):1615–1621
17. Wang H et al (2004) Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84(8):941–951
18. Thornburg NJ, Pathmanathan R, Raab-Traub N (2003) Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 63(23):8293–8301
19. Bancroft CC et al (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99(4):538–548
20. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H (2002) Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene 21(13):2066–2078
21. Pianetti S et al (2001) Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20(11):1287–1299
22. Remon J et al (2014) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev 40(1):93–101
23. Matusan-Ilijas K et al (2013) EGFR expression is linked to osteopontin and Nf-kappaB signaling in clear cell renal cell carcinoma. Clin Transl Oncol 15(1):65–71
24. Biswas DK, Iglehart JD (2006) Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 209(3):645–652
25. Biswas DK et al (2000) Epidermal growth factor- induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 97(15):8542–8547
26. Ahmed KM, Cao N, Li JJ (2006) HER-2 and NF-kappaB as the targets for therapyresistant breast cancer. Anticancer Res 26(6B): 4235–4243
27. Blonska M, Lin X (2011) NF-kappaB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 21(1):55–70
28. Medoff BD et al (2009) CARMA3 mediates lysophosphatidic acid-stimulated cytokine secretion by bronchial epithelial cells. Am J Respir Cell Mol Biol 40(3):286–294
29. Mahanivong C et al (2008) Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 27(9): 1273–1280
30. Jiang C, Lin X (2012) Regulation of NF-kappaB by the CARD proteins. Immunol Rev 246(1):141–153
31. Jiang T et al (2011) CARMA3 is crucial for EGFR-induced activation of NF-{kappa}B and tumor progression. Cancer Res 71(6): 2183–2192
32. Marsigliante S, Vetrugno C, Muscella A (2013) CCL20 induces migration and proliferation on breast epithelial cells. J Cell Physiol 228(9):1873–1883
33. Grabiner BC et al (2007) CARMA3 deficiency abrogrates G-protein-coupled receptorinduced NF-kappaB activation. Genes Dev 21(8):984–986